983P Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial
J. Xu, Qi Wang(Capital University), Zhao Wang(Guangxi University), Jian Wu(Sun Yat-sen University), Zhenggang Ren(Ministry of Education of the People's Republic of China), L. Zhang(Henan Cancer Hospital), Xiaping Chen(Guangdong Provincial People's Hospital), Xianhai Mao(Hunan Provincial People's Hospital), Jianping Xiong(Nanchang University), Shanzhi Gu(Central South University), Lin Xu(Harbin Medical University), Lihua Wu(Zhejiang University), Li Li(Tumor Hospital of Guangxi Medical University), Jie Shen(Xinjiang Medical University), Jingfeng Liu(Fujian Medical University), Guoliang Shao(Zhejiang Cancer Hospital), Y. Zhang, Jiayin Yang(Saudi Center for Organ Transplantation), Tao Yin(Rutgers, The State University of New Jersey)
Cited by 5
Related Papers
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
<p>Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes Combined Pluronic F127 Hydrogel Promote Chronic Diabetic Wound Healing and Complete Skin Regeneration</p>
|International Journal of Nanomedicine|2020|521
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|436